Month: July 2020

BOSTON, July 10, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing Phase 1/2 study of PTR-01 (BBP-589), an intravenously-administered recombinant collagen 7 protein replacement therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). The presentation will be made during the Society for Pediatric Dermatology’s (SPD) 45th Annual Meeting, to be held virtually July 10-12, 2020.The poster presentation, which includes safety and tolerability data observed so far in patients enrolled in cohorts 1-3, will be delivered by Anna L. Bruckner, MD, associate professor of dermatology and pediatrics at University of Colorado School of Medicine. The pre-recorded presentation will be available online to meeting...

MONTREAL, July 10, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company ”),  a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the “TSX”) of the Company’s Notice of Intention to Make a Normal Course Issuer Bid (“NCIB”).  Pursuant to the NCIB, the Company proposes to purchase, from time to time over the next 12 months, if considered advisable, up to 10,856,710 common shares of the Company, being approximately 10% of its public float of 108,567,101 common shares, as of July 6, 2020. As of July 6, 2020, there were a total of 130,938,418 common shares issued and outstanding. Purchases may commence on July 14, 2020 and will conclude on the earlier of the date on which purchases under the bid have been...

MONTRÉAL, 10 juill. 2020 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société »), société pharmaceutique spécialisée et chef de file panaméricaine (ex É.U), a annoncé aujourd’hui l’approbation par la Bourse de Toronto (« TSX ») de l’avis d’intention de la Société de présenter une offre publique de rachat dans le cours normal des activités (« OPRCNA »). En vertu de l’OPRCNA, la Société propose l’achat, au cours des 12 prochains mois, si elle le juge souhaitable, jusqu’à concurrence de 10 856 710 actions ordinaires de la Société, soit environ 10 % de son capital social de 108 567 101 actions ordinaires en date du 6 juillet 2020. En date du 6 juillet 2020, un total de 130 938 418 actions ordinaires étaient émises et en circulation. Les achats peuvent commencer le 14 juillet 2020 et prendront fin à la...

EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEBLiterature review of 65 studies confirms and expands understanding of substantial disease burden of RDEB with considerable clinical, economic and humanistic impact on patients and their familiesNEW YORK and CLEVELAND, July 10, 2020 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two poster presentations related to its clinical program for recessive dystrophic epidermolysis bullosa (RDEB) were featured at the Society for Pediatric Dermatology (SPD) 45th Annual Meeting. The first poster includes a detailed analysis of patients with RDEB in the EB-101 Phase 1/2a trial showing that wound healing following EB-101 treatment was associated...

MADISON, Wis., July 10, 2020 (GLOBE NEWSWIRE) — The Alliant Energy Corporation (NASDAQ: LNT) Board of Directors today declared a quarterly cash dividend of $0.38 per share payable on August 17, 2020, to shareowners of record as of the close of business on July 31, 2020.Dividends on common stock have been paid for 299 consecutive quarters since 1946.Alliant Energy Corporation (NASDAQ: LNT), headquartered in Madison, Wis., provides regulated electric and natural gas service to 970,000 electric and 420,000 natural gas customers across Iowa and Wisconsin. Alliant Energy’s mission is to deliver energy solutions and exceptional service customers and communities count on – safely, efficiently and responsibly. Interstate Power and Light Company and Wisconsin Power and Light Company are Alliant Energy’s two public utility subsidiaries. Alliant...

VANCOUVER, British Columbia, July 10, 2020 (GLOBE NEWSWIRE) — Thor Explorations Ltd. (TSX VENTURE: THX) (“Thor” or the “Company”) is pleased to announce that it has closed a first tranche in it previously announced brokered private placement raising a total of C$12.5 million (US$9.2m) through the issuance of 69,479,167 common shares at a price of C$0.18 per share.After the closing of the private placement, the total number of shares outstanding now is 615,126,612.H&P (Advisory) Limited and Paradigm Capital Inc. acted as Joint Lead Agents to the Private Placement. The Agents received a cash commission on the Offering of 6% of the gross proceeds of the Offering.In connection with the private placement, the Joint Lead Agents arranged for each subscriber to purchase from certain selling shareholders, one common share, for every two...

DALLAS, July 10, 2020 (GLOBE NEWSWIRE) — LGI Homes, Inc. (Nasdaq:LGIH) today announced the opening of three communities in the Dallas-Fort Worth market conveniently located throughout the metroplex: Hampton Meadows, Willowwood and Chisholm Springs.Located just north of Denton in Sanger, Texas, in the charming community of Willowwood, LGI Homes will construct 174 single-family homes ranging in size from 1,649 square feet to just over 2,600 square feet. In this community, LGI Homes is offering four popular floor plans in addition to two brand-new designs. Every new home will feature LGI Homes’ CompleteHome™ package offering remarkable included upgrades. Energy-efficient Whirlpool® appliances, granite countertops, wood cabinetry with crown molding detail and luxury vinyl-plank flooring are just a few of the impressive upgrades included...

Target Enrollment Completed Ahead of ScheduleTopline Data Expected Fourth Quarter 2020Results of Interim Analysis from the First 50 Percent of Participants Expected in September 2020NEW YORK, July 10, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has met its target enrollment of approximately 470 participants in its Phase 3 RELIEF trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg, ahead of schedule. TNX-102 SL is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. An optional interim analysis is expected in September 2020 of the first 50 percent of randomized participants evaluable for efficacy, with Independent Data Monitoring...

            NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESAURORA, Ontario, July 10, 2020 (GLOBE NEWSWIRE) — Tri Origin Exploration Ltd. (TSX-V: TOE) (the “Company”) is pleased to announce that it intends to restructure the Company’s share capital (the “Restructuring”) to assist in positioning itself to move ahead with financing activities and commence diamond drilling programs at its key gold projects in the Canadian Shield of Ontario.The Restructuring will be conducted by way of a share consolidation of the share capital of the Company on a ratio of one (1) post consolidation share for every five (5) pre-consolidation shares. The Company currently has 127,299,639 common shares issued and outstanding. The Company also expects that, subject to receipt of final approval of TSX Venture...

Full Year Revenue of Approximately $62.3 MillionCompany Focus on Shareholder Value Creation, Cash Preservation, Expense Reduction, Workforce Efficiency and Operational SynergiesFARMINGDALE, N.Y., July 10, 2020 (GLOBE NEWSWIRE) — Misonix, Inc. (Nasdaq: MSON) (“Misonix,” the “Company,” “we,” “us” or “our”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced preliminary unaudited fiscal 2020 fourth quarter revenue for the three months ended June 30, 2020.Fiscal Fourth Quarter RevenueMisonix’s revenue for the three months ended June 30, 2020 was approximately $13.5 million, compared to $9.8 million in the prior year period. Due to Misonix’s acquisition of Solsys Medical, which was completed in the first fiscal quarter of 2020, the prior year...